Table 4. Individual patient outcomes.
DS, deep sequencing for IgH rearrangement; DUCBT, double umbilical cord blood transplant; FC, flow cytometry; HUCT, haplo-umbilical cord transplant; MTX, methotrexate; Peg, pegaspariginase; Pred, prednisone; qPCR, quantitative PCR for bcr-abl transcript; RD, related donor; TCD, T cell–depleted; UD, unrelated donor; Vinc, vincristine; NA, not available.
| Patient ID | Age | Cytogenetics at diagnosis | Salvage therapy | Disease response to salvage therapy | Disease response to CAR T cells | Allo-SCT |
|---|---|---|---|---|---|---|
| MSK-ALL01 | 66 | Normal karyotype | Vinc/Pred/Peg | MRD+ by DS | MRD− by DS | 10/10 TCD RD at 64 days post |
| MSK-ALL03 | 56 | Normal karyotype | Vinc/Pred/Peg | MRD− by FC | MRD− by FC | 10/10 TCD MRD at 43 days post |
| MSK-ALL04 | 59 | t(9;11), 9p21 deletion | Vinc/Pred | Refractory disease, 63% blasts in BM | MRD− by DS | Ineligible because of medical contraindications |
| MSK-ALL05 | 58 | 9p21 deletion | High-dose cytarabine/mitoxantrone | Refractory disease, 70% blasts in BM | MRD− by DS | TCD DUCBT at 69 days post |
| MSK-ALL06 | 23 | Normal karyotype | Modified NYII Consolidation I (27) |
MRD+ | MRD− by DS | 8/10 TCD UD at 121 days post |
| MSK-ALL07 | 30 | 9q isochrome, 12p13 deletion | Vinc/Pred/Peg | Refractory disease, 5–10% blasts in BM | MRD− by DS | Declined |
| MSK-ALL08 | 74 | Complex including 11q23 deletion | MTX | BM-negative, +extramedullary disease | No response | No response |
| MSK-ALL09 | 23 | NA | Modified NYII Consolidation I |
MRD+ by FC | MRD− by FC, MRD+ by DS | Ineligible because of medical contraindications |
| MSK-ALL10 | 27 | Normal | Modified NYII Consolidation I |
MRD− by FC | MRD− by FC | Ineligible because of medical contraindications |
| MSK-ALL11 | 32 | Ph+ | Vinc/Peg | MRD+ by qPCR | MRD− by qPCR | 10/10 UD at ~90 days post |
| MSK-ALL12* | 42 | Ph+ | Clofarabine | Refractory disease, 97% blasts in BM | No response | No response |
| MSK-ALL13* | 36 | Ph+ | Inotuzumab | Refractory disease, 60% blasts in BM | MRD− by DS and qPCR | Declined |
| MSK ALL14 | 60 | NA | Vinc/Pred/Peg | Refractory disease, 52% blasts in BM | MRD− by FC | HUCT at ~60 days post |
| MSK ALL15* | 27 | t(2;12), monosomy 7 | L20 (28) | Refractory disease, 23% blasts in BM | MRD− by DS | 10/10 UD at 49 days post |
| MSK- ALL16* | 63 | Ph+, 11q deletion | POMP (29) | MRD+ by qPCR | MRD+ by qPCR | No response |
| MSK-ALL17 | 59 | Complex | Vinc/Pred | Refractory disease, 85% blasts in BM | MRD− by FC | Awaiting allo-SCT evaluation |
*
Enrolled and treated after an allo-SCT.